 reuters    four u s  senators have asked the senate judiciary committee to launch an investigation into a deal drugmaker allergan plc  agn n  struck with a native american tribe to protect some of its patents from generic challenge  according to a letter seen by reuters  democrats maggie hassan  sherrod brown  bob casey and richard blumenthal in the letter to judiciary committee chairman chuck grassley and ranking member dianne feinstein on wednesday called allergan s deal  a blatantly anti competitive attempt to shield its patents from review and keep drug prices high   allergan said on sept   that it was transferring patents on its dry eye medication restasis to upstate new york s saint regis mohawk tribe  which agreed to exclusively license them back to the company in exchange for ongoing payments  allergan said in an emailed response to a reuters request for comment that it met last week with the staffs of senators brown and hassan to provide detailed briefings on the agreement   we would welcome the opportunity to provide additional briefings for these senators  as well as the opportunity to brief senators casey and blumenthal  and answer any questions they may have   allergan said in the email   the tribe and company have said that the tribe s sovereign status shields the patents from review by the u s  patent trial and appeal board  an administrative court empowered to invalidate patents  on friday  the tribe asserted this immunity in an ongoing administrative proceeding brought by generic drugmakers led by mylan nv  myl o   which are seeking to invalidate allergan s patents to introduce cheaper versions of restasis to the market   mylan has called allergan s deal with the tribe a  sham transaction  and said the tribe should not be allowed to invoke immunity to prevent administrative review  some patent lawyers have noted that the patent board has recognized the immunity of state entities like public universities  and tribal immunity is considered to be an even stronger shield  generic drug companies often seek to challenge brand name drug patents through administrative proceedings  which are cheaper and faster than federal court litigation  allergan has said it would not invoke the tribe s immunity in federal court  